Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Ajai ChariMonique C MinnemaJesus G BerdejaAlbert OriolNiels W C J van de DonkPaula Rodríguez-OteroElham AskariMaría-Victoria MateosLuciano José Megale CostaJo CaersRaluca VeronaSuzette GirgisShiyi YangRachel B GoldsmithXiang YaoKodandaram PillarisettiBrandi W HilderJeffery RussellJenna D GoldbergAmrita KrishnanPublished in: The New England journal of medicine (2022)
Cytokine release syndrome, skin-related events, and dysgeusia were common with talquetamab treatment but were primarily low-grade. Talquetamab induced a substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma. (Funded by Janssen Research and Development; MonumenTAL-1 ClinicalTrials.gov number, NCT03399799.).
Keyphrases
- multiple myeloma
- low grade
- high grade
- high glucose
- diabetic rats
- acute lymphoblastic leukemia
- drug induced
- acute myeloid leukemia
- soft tissue
- case report
- oxidative stress
- endothelial cells
- diffuse large b cell lymphoma
- wound healing
- hodgkin lymphoma
- combination therapy
- replacement therapy
- stress induced
- smoking cessation